Glimepiride, > = 98 %(HPLC) ,SOLIDE

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Glimepiride is currently used to treat type 2 diabetes.

Glimepiride has been used: as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)as a sulfonylurea ATP-sensitive potassium channel (K_ATP) channel inhibitor in breast cancer MDA-MB-231 cellsin glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac K_ATP channels activated by pinacidil with an IC₅₀ of 6.8 nM.

Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.

Packaging

50, 250 mg in glass bottle